Montelukast Zydus (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Zydus, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed in the maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Montelukast is a leukotriene receptor antagonist used to manage conditions driven by leukotriene‑mediated inflammation. - Asthma: reduces frequency of symptoms and improves overall disease control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Adverse reactions may occur with Montelukast use.

Common Side Effects: - Headache: mild to moderate head pain. - Abdominal pain: discomfort in the stomach area. - Cough: transient irritation of the throat. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Mood changes: depression or suicidal thoughts.

Montelukast should be used with attention to specific safety considerations. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; consider potential risks. - Age: not recommended for children under 12 months. - Drug interactions: review concomitant medications, especially enzyme‑inducing agents. - Renal/hepatic impairment: assess need for dose adjustment. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Montelukast may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma levels of montelukast. - Rifampin: may decrease therapeutic efficacy. - Ketoconazole: may increase montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - Beta‑agonists: additive bronchodilation effect may occur.